Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Pharmacokinetic Models: Comparison and Selection Criterion01:26

Pharmacokinetic Models: Comparison and Selection Criterion

149
Physiological and compartmental models are valuable tools used in studying biological systems. These models rely on differential equations to maintain mass balance within the system, ensuring an accurate representation of the dynamic processes at play.
Physiological models take a detailed approach by considering specific molecular processes. They can predict drug distribution, metabolism, and elimination changes, providing a comprehensive understanding of how drugs interact with the body.
149
Pharmacokinetic Models: Overview01:20

Pharmacokinetic Models: Overview

1.1K
Pharmacokinetic models utilize mathematical analysis to achieve a detailed quantitative understanding of a drug's life cycle within the body. They are instrumental in simulating a drug's pharmacokinetic parameters, predicting drug concentrations over time, optimizing dosage regimens, linking concentrations with pharmacologic activity, and estimating potential toxicity.
There are three primary types of models: empirical, compartment, and physiological. Empirical models, with minimal...
1.1K
Physiological Pharmacokinetic Models: Incorporating Hepatic Transporter-Mediated Clearance01:07

Physiological Pharmacokinetic Models: Incorporating Hepatic Transporter-Mediated Clearance

80
Drug transporters are critical in drug absorption, distribution, and excretion processes. They should be included in physiological-based pharmacokinetic (PBPK) models, which help predict human drug disposition. However, predicting this is challenging during drug development, especially when liver transport is involved. However, with a realistic representation of body transport processes, an accurate model may be possible.
A recent model describes pravastatin's hepatobiliary excretion,...
80
Three-Compartment Open Model01:06

Three-Compartment Open Model

428
The three-compartment open model is a pharmacokinetic model used to describe the distribution and elimination of drugs following extravascular administration. It comprises a central compartment representing the plasma and two peripheral compartments. The highly perfused peripheral compartment represents organs and tissues with a rich blood supply, such as the liver, kidneys, and lungs. The scarcely perfused peripheral compartment represents tissues with lower blood supply, such as adipose...
428

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Predicting First-in-Human Pharmacokinetics: Comparative Evaluation of Standard PBPK, High-Throughput PBPK, and Machine Learning.

Molecular pharmaceutics·2026
Same author

Time-dependent pattern of liver injury biomarkers in neonates with hypoxic-ischemic encephalopathy undergoing therapeutic hypothermia.

European journal of pediatrics·2026
Same author

Neonatal PBPK model of midazolam and its metabolites for perinatal asphyxia and therapeutic hypothermia.

British journal of clinical pharmacology·2026
Same author

PQRI Workshop: Model-Informed Drug Development (MIDD) Approaches in Pediatric Formulation Development.

The AAPS journal·2026
Same author

Combining the novel all-human co-cultured hepatocytes system with physiologically based pharmacokinetic modeling to assess the translatability of cytochrome P450 and uridine 5'-diphospho-glucuronosyltransferase induction data.

Drug metabolism and disposition: the biological fate of chemicals·2026
Same author

Open Systems Pharmacology Community Conference (OSP-CC) Proceedings 2025.

CPT: pharmacometrics & systems pharmacology·2026

Related Experiment Video

Updated: Sep 11, 2025

Human Liver Microphysiological System for Assessing Drug-Induced Liver Toxicity In Vitro
11:06

Human Liver Microphysiological System for Assessing Drug-Induced Liver Toxicity In Vitro

Published on: January 31, 2022

4.7K

Optimization of In Vitro CYP3A4 TDI Assay Conditions and Use of Derived Parameters for Clinical DDI Risk Assessment

Alessandra Pugliano1,2, Aynur Ekiciler3, Lena Preiss3

  • 1Roche Pharmaceutical Research and Early Development, Roche Innovation Center Basel, Grenzacherstrasse 124, F. Hoffmann-La Roche Ltd, CH-4070, Basel, Switzerland. alessandra.pugliano@roche.com.

The AAPS Journal
|August 13, 2025
PubMed
Summary

Optimizing in vitro conditions for Cytochrome P450 3A4 (CYP3A4) time-dependent inhibition assays improves drug-drug interaction predictions. Physiologically-based pharmacokinetic models offer better accuracy than mechanistic static models for CYP3A4 TDI assessment.

Keywords:
CYP3A4drug-drug interactionsmechanistic static modelingphysiologically-based pharmacokinetic modelingtime-dependent inhibition

More Related Videos

Mass Spectrometry and Luminogenic-based Approaches to Characterize Phase I Metabolic Competency of In Vitro Cell Cultures
10:44

Mass Spectrometry and Luminogenic-based Approaches to Characterize Phase I Metabolic Competency of In Vitro Cell Cultures

Published on: March 28, 2017

9.9K
A Combined 3D Tissue Engineered In Vitro/In Silico Lung Tumor Model for Predicting Drug Effectiveness in Specific Mutational Backgrounds
13:34

A Combined 3D Tissue Engineered In Vitro/In Silico Lung Tumor Model for Predicting Drug Effectiveness in Specific Mutational Backgrounds

Published on: April 6, 2016

10.3K

Related Experiment Videos

Last Updated: Sep 11, 2025

Human Liver Microphysiological System for Assessing Drug-Induced Liver Toxicity In Vitro
11:06

Human Liver Microphysiological System for Assessing Drug-Induced Liver Toxicity In Vitro

Published on: January 31, 2022

4.7K
Mass Spectrometry and Luminogenic-based Approaches to Characterize Phase I Metabolic Competency of In Vitro Cell Cultures
10:44

Mass Spectrometry and Luminogenic-based Approaches to Characterize Phase I Metabolic Competency of In Vitro Cell Cultures

Published on: March 28, 2017

9.9K
A Combined 3D Tissue Engineered In Vitro/In Silico Lung Tumor Model for Predicting Drug Effectiveness in Specific Mutational Backgrounds
13:34

A Combined 3D Tissue Engineered In Vitro/In Silico Lung Tumor Model for Predicting Drug Effectiveness in Specific Mutational Backgrounds

Published on: April 6, 2016

10.3K

Area of Science:

  • Pharmacology and Drug Metabolism
  • Drug Development and Safety Assessment

Background:

  • Cytochrome P450 3A4 (CYP3A4) is crucial for drug metabolism, and assessing its time-dependent inhibition (TDI) is vital during drug development.
  • Predicting in vivo drug-drug interaction (DDI) risk from in vitro TDI data often leads to overestimation, posing challenges for accurate risk assessment.

Purpose of the Study:

  • To investigate the impact of varying in vitro TDI assay conditions in human liver microsomes (HLM) on the prediction accuracy of CYP3A4-related DDIs.
  • To identify optimal incubation parameters for in vitro TDI assays to enhance the reliability of DDI predictions for marketed drugs.

Main Methods:

  • Evaluated 32 marketed drugs for CYP3A4-related DDIs using different in vitro TDI assay conditions in human liver microsomes (HLM).
  • Determined optimal incubation parameters by considering assay sensitivity and in vivo DDI prediction accuracy using mechanistic static modeling (MSM).
  • Compared prediction accuracy of optimized parameters using mechanistic static modeling (MSM) and physiologically-based pharmacokinetic (PBPK) models.

Main Results:

  • Identified optimal incubation parameters: 40 min pre-incubation for precipitants and 10 min incubation for midazolam (10 μM) at 0.1 mg/mL HLM.
  • Mechanistic static modeling (MSM) still showed a tendency to overestimate DDI magnitude (AFE=4.83, AAFE=4.87) even with optimized conditions.
  • Physiologically-based pharmacokinetic (PBPK) models demonstrated improved predictions (AFE=1.94, AAFE=2.13), with 60% of predicted AUCR within a twofold range.

Conclusions:

  • Optimizing in vitro TDI incubation conditions is critical for improving the accuracy of DDI predictions.
  • Physiologically-based pharmacokinetic (PBPK) models provide more accurate predictions of clinical CYP3A4 TDI effects compared to mechanistic static models.
  • Understanding the benefits and limitations of both MSM and PBPK models is essential for robust DDI risk assessment in drug development.